The comprehensive landscape of TTMV::RARA fusiondriven acute myeloid leukemia: from viral integration mechanisms to clinical outcomes

作者信息Shu Sun, Yongjing Liu, Qing-Yu Xu, Jiayu Wang, Li Chen, Zhanrui Cheng, Wei Gao, Huili Wang, Bei Yang, Haiyan Wang, Lijun Wen, Jian Xiao, Jiacheng Lou, Haibo Yu, Na Li, Feng Wang, Yangyang Xie, JinGang Wang, Xianjing Wang, Hongjuan Xue, Kun Chen, Yin Wu, Leping Zhang, Ke Li, Shuhong Shen, Suning Chen, Huan-You Wang, KanKan Wang, Jinyan Huang, Hong-Hu Zhu
PMID41230695
期刊Haematologica
发布时间2026-04-01
DOI10.3324/haematol.2025.288721

摘要

Acute myeloid leukemia (AML) with TTMV::RARA fusion represents a novel subtype driven by torque teno mini virus (TTMV) integration into the retinoic acid receptor α (RARA) locus, while current understanding of its molecular features and clinical presentation relies predominantly on isolated case observations. Here, we characterize a large and independent cohort (N=25) through integrative analysis of clinical-omics data, uncovering unique features that distinguish it from classic acute promyelocytic leukemia (APL) and other AML subtypes. Our findings reveal that TTMV integrates exclusively within intron 2 of the RARA gene via microhomology-mediated end joining, forming functional TTMV::RARA transcripts. Clinically, patients harboring this fusion were predominantly pediatric (72%, age <18 years) and often presented with extramedullary diseases (24% with myeloid sarcoma, 16% with central nervous system infiltration). Blasts displayed APL-like morphology and immunophenotype but lacked PML::RARA, instead harboring TTMV::RARA with recurrent i(17)(q10) abnormalities (24%). Unsupervised clustering revealed it as a molecularly distinct subgroup. Transcriptomic profiling identified a Wnt-activated/extracellular matrix-dysregulated signature, driving leukemogenesis via dual mechanisms of clonal expansion and metastatic pathways. Despite achieving a 96% complete remission rate with induction therapy, long-term outcomes were significantly inferior, with 2-year event-free survival and relapse-free survival rates of 53.6% and 53.8%, respectively. Hematopoietic stem cell transplantation achieved durable remission in nine of 11 patients, particularly those with extramedullary disease or i(17)(q10) abnormalities. Conclusively, this work establishes TTMV::RARA as a novel AML subtype, highlighting the need for viral screening in APL-like cases and hematopoietic stem cell transplantation prioritization for this subset.

实验方法

产品清单

名称品牌货号
Salmon--v1.9.0
DESeq2--v1.40.2
R软件--v4.4.0
GraphPad Prism--v10.1.2